1. Carli N. Allendorf, RN, MSN, ACNP-BC
21222 Endsley Avenue, Rocky River, OH 44116
614-352-8603 carli.allendorf@abbvie.com; carligr@aol.com
Education
Current Role
Vanderbilt University, Nashville, TN
 Master of Science in Nursing
Miami University, Oxford, OH
 Associate in Applied Science in Nursing
Thought Leader Liaison within the hematology franchise at Abbvie Inc. and Acute Care Nurse
Practitioner
Experience Thought Leader Liaison Abbvie Inc. Midwest Region
October 2016-current
 Develops, implements and maintains accountability for interactions and feedback with national
hematology thought leaders
 Maintains communication with the brand team to assure a coordinated approach to collaboration
with national hematology thought leaders, including coordination of the speakers bureau, advisory
boards and consulting agreements
 Partners with internal cross functional partners including but not limited to sales, marketing, medical
affairs, legal and compliance
Regional Marketing Sr. Manager
May 2014-September 2016 Amgen Biopharmaceutical Company Great Lakes Region
 Supports the hematology sales force by developing, increasing effectiveness of, and ensuring
compliance for field based marketing initiatives
 Assumes responsibility for recruitment, surveillance, and active coaching of hematology speakers
 Provides high level networking within the Great Lakes region with opinion leaders specializing in
hematology increasing overall organizational access
 Assists with commercial marketing advisory boards and consulting opportunities
 Partners with the field sales team members, sales operations, and marketing sales analytics to
better understand regional and local marketing trends
Oncology Clinical Specialist
Sept 2012-May 2014 Amgen Biopharmaceutical Company Central Ohio
 strategic clinical sales role that results in increased appropriate utilization of Amgen products by
selling through clinical expertise and partnership with key customers with a focus on consistent
identification of appropriate patients
 affects territory sales by executing a plan of action marketing strategy as directed by the nurse sales
managers and deployed by district managers including but not limited to: delivering branded sales
messages, executing strategic activities, scheduling and implementing clinical education programs,
and achieving or exceeding sales goals in close collaboration with district biopharmaceutical sales
representatives
 provides support to biopharmaceutical sales representatives with office managers, buyers, and

2. Carli N. Allendorf, RN, MSN, ACNP-BC
21222 Endsley Avenue, Rocky River, OH 44116
614-352-8603 carli.allendorf@abbvie.com; carligr@aol.com
reimbursement coordinators, providing feedback on marketing strategies, reviewing sales activity,
and participating in territory analysis
Acute Care Nurse Practitioner
March 2009-September 2012 James Cancer Center & Solove Research Institute Columbus, OH
 outpatient hematology clinic specializing in multiple myeloma and amyloidosis from initial diagnosis
to end-of-life care issues for over 600 patients collaborating with three physicians
 managed 30-40 patients per clinic day ranging in acuity level, actively receiving various
chemotherapy regimens including phase-two and three clinical trial pharmaceutical agents, in
addition to assisting in pre and post stem cell transplant management while often precepting
residents and medical students
Acute Care Nurse Practitioner
October 2006-March 2009 James Cancer Center & Solove Research Institute Columbus, OH
 inpatient hematology service specializing in acute leukemia, myelodysplastic syndrome, and
lymphoma from initial diagnosis to end-of-life care issues; managed 5-9 patients per weekday and up
to 30 patients on weekends ranging in acuity level and actively receiving various chemotherapy
regimens
 performed various bedside patient procedures, including bone marrow biopsies, lumbar punctures,
intrathecal chemotherapy administration, and ABGs while often precepting residents, medical
students, and colleagues
Registered Nurse
August 2004-August 2005 Vanderbilt University Hospital Nashville,TN
 28-bed medical/surgical unit providing care for pre and post-op surgical patients, including general
medicine, hepato-biliary, ENT, vascular and plastic surgery patients; managed 5-6 patients of various
acuity levels per shift
 fulfilled the role of a preceptor to new employees on the medical unit
Certifications
Professional
Committees
 Acute Care Nurse Practitioner
 Registered Nurse, Ohio
 Certificate to Prescribe and DEA
 Amgen Women’s Interactive Network
-May 2015-September 2016
 Onyx Blincyto Advisors Committee
-February 2015-January 2016

3. Carli N. Allendorf, RN, MSN, ACNP-BC
21222 Endsley Avenue, Rocky River, OH 44116
614-352-8603 carli.allendorf@abbvie.com; carligr@aol.com
Professional
Memberships
Abstracts &
Publications
 Amgen Council of Sales Advisors Committee
-October 2013-May 2014
 Pharmacy & Therapeutics Committee, The James Cancer Center
-June 2010-June 2012
 Institute for Medical Education & Research (IMER): Multiple Myeloma Mentorship Program
-June 2010-June 2011
 James Professional Development Council
-January 2007-March 2009
 Oncology Nursing Society
 Greenfield, Carli N. (December 2011). Your FAQs: What are the different types of amyloidosis
and what treatment options are available? The Oncology Nurse, 4 (8). Retrieved from
http://www.theoncologynurse.com
 Greenfield, Carli N. (December 2011). Your FAQs: What are the different types of amyloidosis and
what treatment options are available? The Oncology Pharmacist, 4 (8). Retrieved from
http://www.theoncologypharmacist.com
 Don M. Benson, Jr., Courtney E. Bakan, Anjali Mishra, Craig C. Hofmeister, Yvonne Efebera,
Brian Becknell, Robert A. Baiocchi, Jianying Zhang, Jianhua Yu, Megan K. Smith, Carli N.
Greenfield, Pierluigi Porcu, Steven M. Devine, Rinat Rotem-Yehudar, Gerard Lozanski, John
C. Byrd, and Michael A. Caligiuri . “The PD-1 / PD-L1 axis modulates the natural killer cell
versus multiple myeloma effect: a therapeutic target for CT-011, a novel, monoclonal anti-PD-1
antibody." Blood First Edition Paper, prepublished online May 11, 2010; DOI 10.1182/blood-
2010-02-271874. Blood, 11 May 2010, Vol. 0, No. 2010, pp. 201002271
 Sherry Mori,1,5 Brooke S. Crawford,1,5 Julianna V.F. Roddy,1,5 Gary Phillips,2 Pat Elder,3,5 Craig
C. Hofmeister,3,4,5 Yvonne A. Efebera,3,4,5 Carli N. Greenfield,5 Karen Rose,5 and Don M.
Benson, Jr.3,4,5 (Presenting author). “Serum free light chains add to M-protein by immunofixation in
response assessment of newly diagnosed patients with myeloma receiving novel therapies and may
hold unique, a prior prognostic power prior to HDC/SCT.” Hematologica,…
References  Available upon request

4. Carli N. Allendorf, RN, MSN, ACNP-BC
21222 Endsley Avenue, Rocky River, OH 44116
614-352-8603 carli.allendorf@abbvie.com; carligr@aol.com